There is also evidence that nuclear IGF‐1R associates with response to IGF‐1R antibody therapy in patients with sarcoma [16], suggesting that nuclear IGF‐1R indicates IGF dependence and could be a potential biomarker for response to IGF‐axis targeting treatments. This evidence concerns the gene IGF1 and sarcoma.